TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1657527
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser trabeculoplasty (ALT) followed by medical treatment if needed to control intraocular pressure (IOP)
Study: 7204470
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment on a Thomas' splint
Study: 31088302
Drug: Extended thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended thromboprophylaxis with oral anticoagulation
Study: 18496372
Drug: Intravenous alanyl‐glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alanyl‐glutamine supplementation (0.3 g/kg x day(‐1) from day 4 until day 17) and intravenous growth hormone (50 microg/kg x day(‐1) from day 10 onward)
Study: 10920133
Drug: PEG‐rHuMGDF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF administered subcutaneously after chemotherapy
Study: 10920133
Drug: PEG‐rHuMGDF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF administered before chemotherapy
Study: 10920133
Drug: PEG‐rHuMGDF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF administered after chemotherapy
Study: 10920133
Drug: PEG‐rHuMGDF administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐rHuMGDF administered alone
Study: 1637696
Drug: etretinate TL-01
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etretinate TL-01 combination therapy (re-TL-01)
Study: 3931143
Drug: IV doses
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV doses (0.2, 0.4, or 0.6 mg/kg)
Study: 3931143
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses (2, 3, or 4 mg/kg)
Study: 29409833
Drug: Algorithm for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm for abortion intravenous sedation dosing (AAID)
Study: 26349796
Drug: Three-in-one injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-in-one injection comfort system (ICS)
Study: 26349796
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent lidocaine pump spray
Study: 11554235
Drug: Tropisetron (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.2 mg/kg/24 h intravenously)
Study: 9692122
Drug: Nasal beclomethasone
Normalized name: beclomethasone Nasal Spray
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal beclomethasone dipropionate (BDP) 400 micrograms daily
Study: 9692122
Drug: Nasal anti-histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal anti-histamine levocabastine 200 micrograms daily
Study: 3168450
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Mifepristone
Study: 30075886
Drug: Carvacrol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvacrol (1.2 mg/kg/day) for two months
Study: 16624147
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy in OSAHS group
Study: 16624147
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy in OSAHS with CHD group
Study: 27163518
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen (VE) therapy, 0.5g promestriene cream twice a week for 6 weeks before surgery
Study: 27163518
Drug: Non-vaginal estrogen
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vaginal estrogen (non-VE) therapy, no pharmacologic preparation before surgery
Study: 22567139
Drug: Syrups of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrups of combination ART including Nevirapine, Zidovudine, Abacavir and Lamivudine
Study: 22567139
Drug: Scored adult-dose
Normalized name: hepatitis A vaccine (inactivated) strain HM175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scored adult-dose tablets prescribed according to WHO weightband tables
Study: 22567139
Drug: Syrups
Normalized name: Syrups, hydrolyzed starch, dehydrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrups
Study: 19673898
Drug: subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous sumatriptan 6 mg
Study: 6973990
Drug: Fluproquazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone (200 mg)
Study: 6973990
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (1000 mg)
Study: 31227028
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 or 50 mg/day for 2 months
Study: 20456070
Drug: Standard multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multimodal inpatient treatment
Study: 2182423
Drug: Sequential decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential decision strategy
Study: 29979445
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg over 10 minutes before anesthesia induction and then 0.5 μg/kg/h until peritoneal closure)
Study: 26803950
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A injections (BoNT-A) in the parotid glands only
Study: 25078309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with ribavirin (group 1)
Study: 25078309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks without ribavirin (group 2)
Study: 25078309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks with ribavirin (group 3)
Study: 25078309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks without ribavirin (group 4)
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL transcript levels >10% at 3 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL transcript levels >1-10% at 3 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL transcript levels ≤1% at 3 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with >35% Philadelphia chromosome-positive metaphases at 3 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with ≤35% Philadelphia chromosome-positive metaphases at 3 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL transcript levels >1% at 6 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with BCR-ABL transcript levels ≤1% at 6 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with >0% Philadelphia chromosome-positive at 6 months
Study: 22446502
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment with 0% Philadelphia chromosome-positive at 6 months
Study: 11764109
Drug: Group G:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G: Saliva contamination
Study: 1284157
Drug: Placebo (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (i.v. 10-ml bolus)
Study: 1818002
Drug: Atenolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (5 mg over 5 min)
Study: 2857523
Drug: Beta-blockade therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade therapy (BB) with metoprolol, titrated from 12.5 to 50 mg twice daily, final average dose 61 mg/day
Study: 2857523
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (C) alone
Study: 2857523
Drug: Beta-blockade therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockade therapy (BB)
Study: 31427046
Drug: Quarterly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quarterly fremanezumab (675 mg month 1; placebo months 2 and 3)
Study: 31427046
Drug: Monthly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly fremanezumab (225 mg in episodic migraine and 675 mg in chronic migraine month 1; 225 mg months 2 and 3)
Study: 17908184
Drug: Lotion treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion treatment
Study: 14732734
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral melatonin (2.5 mg) intake 1 hour before sleep for 3 weeks
Study: 14732734
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of melatonin (2.5 mg)
Study: 7852749
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg per day
Study: 7852749
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg per day
Study: 7852749
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg retard twice a day
Study: 7852749
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 weeks prior to treatment)
Study: 2789428
Drug: Exogenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous recombinant human EGF (hEGF) infusion (0.25-1.0 micrograms/kg)
Study: 2789428
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pentagastrin
Study: 31530611
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (4.4 g/day DHA orally)
Study: 31530611
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal fat supplement of vegetable oil)
Study: 26466913
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus psychotherapy (pyridoxine hydrochloride 40 mg daily for 3 weeks + mindfulness-based cognitive therapy in eight 50 min sessions over 3 weeks)
Study: 26466913
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (pyridoxine hydrochloride 40 mg daily for 3 weeks)
Study: 15687411
Drug: Macronutrient content
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Macronutrient content (e.g., low-fat vs. low-carbohydrate diets)
Study: 11278151
Drug: Other antipsychotic
Normalized name: Other antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antipsychotic drugs (comparison group)
Study: 10028794
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosage of 6 mg/kg of elemental iron (Group A)
Study: 10028794
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral dosage of 6 mg/kg of elemental iron, 3 days a week (Group B)
Study: 7986970
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg t.d.s. with meals plus amoxycillin 750 mg t.d.s. with meals for 10 days
Study: 7986970
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg each evening for 6 weeks (for ulcer healing)
Study: 7986970
Drug: Clarithromycin and
Normalized name: lansoprazole, clarithromycin and tinidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin and amoxycillin therapy
Study: 113217
Drug: Atenolol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (selective beta-1 blocker)
Study: 30623736
Drug: Intracanal cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracanal cryotherapy (20 mL sterile cold saline solution at 2.5 °C for 5 min)
Study: 30623736
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sterile saline solution at room temperature)
Study: 27323324
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) plus physical therapy
Study: 27323324
Drug: Sham shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham shock wave plus physical therapy
Study: 23421363
Drug: Texas Implementation
Normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Texas Implementation of Medication Algorithm (TIMA) for Bipolar Disorder
Study: 22117977
Drug: Subcutaneous transposition
Normalized name: CONNECTOR,ENFIT TRANSITIONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous transposition
Study: 15299099
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (HSC infusion)
Study: 9096446
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) continued for another 12 months
Study: 3698519
Drug: Local beta-receptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local beta-receptor blockade
Study: 4576562
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide and nandrolone decanoate
Study: 27129426
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent inactivated influenza vaccine (HD TIV)
Study: 27129426
Drug: Standard-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose trivalent inactivated influenza vaccine (SD TIV)
Study: 25188774
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 μg) as an adjuvant to levobupivacaine (Chirocaine)
Study: 22024920
Drug: Budesonide/formoterol 160 μg/4.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160 μg/4.5 μg ten inhalations daily for 3 days via Turbuhaler®
Study: 22024920
Drug: Terbutaline 0.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.4 mg ten inhalations daily for 3 days via Turbuhaler®
Study: 361059
Drug: diflucortolone valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: diflucortolone valerate 0.3% ointment
Study: 361059
Drug: clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: clobetasol propionate 0.05% ointment
Study: 23830094
Drug: UMEC/VI 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 62.5/25 mcg
Study: 20829308
Drug: Fluoxetine medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine medication
Study: 19480657
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg p.o.)
Study: 19480657
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg i.v.)
Study: 11224753
Drug: MultiHance (gadobenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiHance (gadobenate dimeglumine) cumulative doses
Study: 8284093
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment at day 10 (n = 14)
Study: 8284093
Drug: Dexamethasone treatment
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone treatment at day 16 (n = 13)
Study: 29283590
Drug: Pacing, Graded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacing, Graded Activity, and Cognitive Behavioral Therapy
Study: 25453534
Drug: Nesiritide therapy
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide therapy
Study: 18586762
Drug: Intravenous C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C.E.R.A. administered once every 2 weeks (Q2W)
Study: 18586762
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) administered once weekly (QW)
Study: 17139037
Drug: Group cognitive-behavioural
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioural therapy
Study: 12919163
Drug: Hydrocortisone 10
Normalized name: hydrocortisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 10 mg with breakfast and 5 mg with lunch (Schedule 1)
Study: 12919163
Drug: Hydrocortisone with
Normalized name: Hydrocortisone with Aloe
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone with the addition of 5 mg with the evening meal (Schedule 2)
Study: 12919163
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/15 kg body weight given per day with breakfast only (Schedule 3)
Study: 12919163
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatment schedules
Study: 8909439
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide T 6 mg/day
Study: 1857947
Drug: Glycine solution
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine solution
Study: 1857947
Drug: Glucose (WHO)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (WHO) solution
Study: 1857947
Drug: Polycose solution
Normalized name: POLYCOSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycose solution
Study: 1857947
Drug: Rice-flour solution
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-flour solution
Study: 6354523
Drug: Percutaneous dihydrotestosterone
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous dihydrotestosterone (DHT) 125 mg twice daily
Study: 6354523
Drug: DHT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHT therapy (group B)
Study: 6354523
Drug: DHT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHT treatment (group A)
Study: 30873752
Drug: Safety and
Normalized name: HYDROCORTISONE ACETATE 10 mg in 1 g TOPICAL CREAM [American Safety and First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and injury prevention contact control (CC)
Study: 29149143
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 mL per side of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg)
Study: 29149143
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 mL per side of 0.25% bupivacaine
Study: 16706948
Drug: Safe Sea
Normalized name: ZINC OXIDE 10.9 g in 100 g TOPICAL LOTION [Safe Sea SPF 30]
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Safe Sea (topical jellyfish sting inhibitor)
Study: 11896407
Drug: RRV-TV (lower-titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-TV (lower-titer formulation: 4 x 10(4) pfu/dose)
Study: 1699861
Drug: Lymphoblastoid interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid interferon therapy
Study: 380609
Drug: Mepivacaine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (250 mg i.v. infusion)
Study: 380609
Drug: Prilocaine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (250 mg i.v. infusion)
Study: 6303793
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CAMP-L: cyclophosphamide, doxorubicin, methotrexate, procarbazine, leucovorin)
Study: 6303793
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (methotrexate/leucovorin followed by cyclophosphamide/doxorubicin at progression)
Study: 29224638
Drug: Bridge therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridge therapy with dalteparin 100 IU/kg twice daily
Study: 29224638
Drug: Perioperative aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative aspirin use
Study: 25432270
Drug: Practice-only condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice-only condition (weekly writing practice; n=39)
Study: 16206354
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily ibandronate
Study: 16206354
Drug: Intermittent ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent ibandronate (interval between doses > 2 mo)
Study: 7011112
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg reproterol
Study: 20011855
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with 10 to 15 mL of 0.5% ropivacaine
Study: 20011855
Drug: Lumbar plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar plexus block with 0.4 mL.kg(‐1) of 0.5% ropivacaine
Study: 17309918
Drug: HIF-1alpha (Ad2/HIF-1alpha/VP16)
Normalized name: 1alpha-hydroxycholecalciferol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIF-1alpha (Ad2/HIF-1alpha/VP16) at doses of 1x10(8) to 2x10(11) viral particles
Study: 11731907
Drug: Valeriana edulis
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valeriana edulis standardized hydroalcoholic extract (450 mg)
Study: 11731907
Drug: Valeriana officinalis
Normalized name: VALERIANA OFFICINALIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valeriana officinalis extract (450 mg)